XM does not provide services to residents of the United States of America.
B
B

Biomerieux


News

Arkema, Flatexdegiro, Mediobanca

EUROPE RESEARCH ROUNDUP-Arkema, Flatexdegiro, Mediobanca Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Flatexdegiro and Mediobanca, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : Berenberg raises to buy from hold * Flatexdegiro AG FTKn.DE : Goldman Sachs raises to buy from neutral * Mediobanca MDBI.MI : Deutsche Bank raises to hold from sell * Orsted ORSTED.CO : Deutsche Bank cuts to hold from buy * Syensqo NV SYENS.
A
A
A
A
A
B
B
B
B
B
C
C
C
C
D
E
G
L
M
M
M
N
O
P
R
S
S
S
U
U
V
W
A
D
S
W

Biomerieux rises on Q3 sales growth above expectations

BUZZ-Biomerieux rises on Q3 sales growth above expectations ** Shares in Biomerieux BIOX.PA rise 3%, after it reports Q3 sales growth above expectations ** The french in-vitro diagnostic company released an 11% organic sales growth in the third quarter compared with the 8.4% expected in a consensus ** The group's growth was supported by a 17.6% gro
B

Biomerieux Q3 2024 +11% Organic Sales Growth At €969M

BRIEF-Biomerieux Q3 2024 +11% Organic Sales Growth At €969M Oct 30 (Reuters) - Biomerieux SA BIOX.PA : +11% ORGANIC SALES GROWTH IN Q3 2024 AT €969M CONFIRMATION OF THE 2024 FULL YEAR REVISED GUIDANCE FY OUTLOOK: CURRENCY EFFECT NEGATIVE IMPACT AROUND €60MLN ON ANNUAL CEBIT VERSUS AROUND €70M PREVIOUSLY Source text: [ https://tinyurl.com/4a
B

Ashmore, Biomerieux, Diasorin

EUROPE RESEARCH ROUNDUP-Ashmore, Biomerieux, Diasorin Oct 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Ashmore, Biomerieux and Diasorin, on Thursday. HIGHLIGHTS * Ashmore ASHM.L : JP Morgan raises target price to 161p from 155p * Biomerieux BIOX.PA : HSBC raises target price to EUR 126 from EUR 120 * Diasorin DIAS.MI : HSBC cuts to hold from buy * Givaudan SA GIVN.S : Citigroup cuts target price to CHF 4650 from CHF 4750 * Oxf
A
A
A
A
B
B
C
D
E
E
G
G
I
L
L
S
T
W
Q
A
A
A
D
U

Biomerieux Receives Marking For Vidas® Vitamin B12 Total

BRIEF-Biomerieux Receives CE-Marking For Vidas® Vitamin B12 Total Oct 15 (Reuters) - Biomerieux SA BIOX.PA : RECEIVES CE-MARKING FOR VIDAS® VITAMIN B12 TOTAL THE COMMERCIAL LAUNCH OF VIDAS® VITAMIN B12 TOTAL IS PLANNED IN SELECT COUNTRIES AT THE END OF 2024, WITH AN EXTENDED ROLLOUT IN Q1 2025 Source text shorturl.at/fD69y Further company covera
B

Air France-KLM, Burberry, Wise

EUROPE RESEARCH ROUNDUP- Air France-KLM, Burberry, Wise Sept 25 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Air France-KLM, Burberry and Wise, on Wednesday. HIGHLIGHTS * Air France-KLM AIRF.PA : JP Morgan raises to overweight from underweight * Burberry BRBY.L : JP Morgan cuts target price to 650p from 800p * Helvetia Holding HELN.S : JP Morgan places stock on its positive catalyst watch list * Orion Oyj ORNBV.HE : Jefferies ra
A
B
B
B
B
B
E
H
H
K
K
A
J
S

Barclays Bank, Ferrari, Volkswagen

EUROPE RESEARCH ROUNDUP-Barclays Bank, Ferrari, Volkswagen Sept 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Barclays Bank, Ferrari and Volkswagen on Monday. HIGHLIGHTS * Barclays Bank BARC.L : Morgan Stanley raises target price to 300p from 290p * Ferrari RACE.MI : Citigroup raises target price to EUR 360 from EUR 334 * Mercedes-Benz Group AG MBGn.DE : Citigroup cuts target price to EUR 60 from EUR 65 * Shell Plc SHEL.L : HSB
A
A
A
B
B
B
B
B
B
B
C
E
E
F
F
F
H
H
H
K
L
P
R
R
R
R
T
U
V
V
A
D
I
I

Sales beat, outlook hike lift Biomerieux shares

BUZZ-Sales beat, outlook hike lift Biomerieux shares ** Shares in Biomerieux BIOX.PA rise 3.4% as the French biotechnology company publishes better-than-expected H1 results, ups guidance ** The group reports sales of 1.9 billion euros for the first half of 2024, a 8.2% beat when compared to a consensus cited by a Midcap analyst ** "The achievement
B

Biomerieux FY Sales Expected To Grow Organically By 8% to 10%

BRIEF-Biomerieux FY Sales Expected To Grow Organically By 8% to 10% Sept 5 (Reuters) - Biomerieux SA BIOX.PA : H1 OPERATING INCOME EUR 288 MILLION VERSUS EUR 208 MILLION H1 NET INCOME GROUP SHARE EUR 215 MILLION VERSUS EUR 162 MILLION H1 ORGANIC SALES EUR 1.90 BILLION 2024 FULL YEAR GUIDANCE REVISED UPWARD 2024 FULL YEAR GUIDANCE: SALES EXPECTED TO
B

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead Aug 30 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 02-Sep-2024 09:00 BAYGn.DE Bayer AG Bayer AG Investor Webinar to Discuss Results from FINEARTS-HFP 02-Sep-2024 09:00 PZU.WA Powszechny Zaklad Ubezpieczen SA Half Year 2024 Powszechny Zaklad Ubezpieczen SA Investor Chat (Polish) 03-Sep-2024 NTS BKWB.S BKW AG Half Year
A
B
B
B
H
R
S
D
S

Top of the Street: Admiral Group, United Utilities, Biomerieux

BUZZ-Top of the Street: Admiral Group, United Utilities, Biomerieux A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Jefferies raises Admiral Group ADML.L to "hold" from "underperform" after the British financial services company exceeded expectations for growth and margin in the first half ** UBS upgrades United Utilities UU.L to "buy" from "neutral" saying the UK water company is trading close to post-2010 multiple lows, while the financial framework th
A
B
U

European stocks rise on rate cut hopes, healthcare sector hits record high

UPDATE 2-European stocks rise on rate cut hopes, healthcare sector hits record high For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Euro zone business activity gets boost from Olympics- PMI ECB policymakers shift focus to September meeting UK's JD Sports gains on Q2 sales rise GN hits bottom of STOXX as earnings miss expectations DB rises after settlement with some plaintiffs STOXX 600 up 0.4% Updated at 1600 GMT By Ankika Biswas and Pra
A
B
J
S
U
E
F
U
G

UBS sees Biomerieux as compelling entry point, starts with 'buy'

BUZZ-UBS sees Biomerieux as compelling entry point, starts with 'buy' ** UBS initiates coverage of French biotechnology company Biomerieux BIOX.PA with "buy", calling it a compelling entry point ** The broker points to the company's new point-of-care technology SPOTFIRE as so game changing compared to existing technologies that it can expand the ma
B

Admiral, Capgemini, Zurich Insurance Group

EUROPE RESEARCH ROUNDUP- Admiral, Capgemini, Zurich Insurance Group Aug 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Admiral, Capgemini and Zurich Insurance Group, on Thursday. HIGHLIGHTS * Admiral ADML.L : Jefferies raises to hold from underperform * Capgemini CAPP.PA : Jefferies cuts target price to EUR 185 from EUR 195 * Glenveagh Properties Plc GLV.I : Jefferies raises to buy from hold * Orsted ORSTED.CO : Deutsche Bank c
A
A
A
B
B
C
D
D
E
E
H
H
O
P
R
S
S
S
S
T
T
T
V
I
U
Z



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.